Isoray, Inc.(ISR)through its subsidiary, IsoRay Medicine, develops and sells medical drugs and instruments for the treatment of cancer and other malignant diseases worldwide. In order to treat prostate, brain, lung, head and neck, gynaecological, pelvic/abdominal, and colorectal tumours, as well as ocular melanoma, the company manufactures CS 1 Cesium 131 brachytherapy seeds.
Isoray, Inc.(ISR)has Market cap of $46.273 million. Yesterday at the normal close the Company’s stock was down -1.12% to $0.5305. However, in the after-hours it dramatically surged 194.06% to $1.56 after the news that U.S. FDA clearance has been received by Isoray Medical for use of C4 Imaging’s Sirius Positive Signal MRI Markers in combination with Cesium-131 brachytherapy seeds.
Sirius is implanted during brachytherapy treatments for prostate cancer that allows brachytherapy seeds to be accurately localized within the prostate after a single post-implantation MRI procedure. All brachytherapy patients can now benefit from MRI assisted brachytherapy, which is also known as MARS (MRI assisted radiosurgery).
Isoray is the world’s only manufacturer of Cesium-131 seeds, usually referred to as Cesium Blu, for prostate cancer treatment. A radioactive isotope called cesium-131 is designed to deliver a highly effective treatment for cancer that preserves healthy tissue and organs. Rapid resolution of side effects enables patients to return to normal life quickly.